An observational study in LONGEVITY 1, Frailty and Aging, sponsored by Center for Strategic Planning, of the Federal Medical and Biological Agency. Recruiting at 1 site in Russian Federation. Open to participants aged 90 Years and older. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by Center for Strategic Planning, of the Federal Medical and Biological Agency · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an observational cohort study of long-living adults (participants aged 90 and above) from the Central Federal District of Russia.
The study seeks to determine the genetic and cellular and molecular determinants of healthy longevity and to assess the impact of lifestyle and socioeconomic and environmental factors on healthy longevity.
The study is expected to result in the development of a panel of markers of healthy longevity and/or a model of healthy aging based on the analysis of all factors under consideration.
The study involves a long-term observation of a cohort of long-living adults. During the first visit, a medical professional will take a detailed medical history and perform a comprehensive geriatric assessment (for 15 geriatric syndromes), and physical examination. The participants will have their biomaterials sampled for basic and extended blood biochemistry testing, telomere length measurement, common urine tests and subsequent biobanking and additional studies: whole genome sequencing, DNA methylation analysis, transcriptome analysis, and 16S RNA sequencing of stool and saliva.
Follow-up checks will be carried out once a year by phone or during additional visits.
The study seeks to identify the genetic, epigenetic, and metagenomic determinants associated with the successful and unsuccessful aging phenotypes, mortality, and survival in long-living individuals.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
This study's planned enrollment of 4,000 is above the median of 225 across 495 observational studies indexed under Frailty.
Browse Frailty studies →Center for Strategic Planning, of the Federal Medical and Biological Agency is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The inclusion of participants will be carried out with the involvement of social services, boarding houses for labor veterans, geriatric centers and other geriatric services in the central region of Russia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Long-living individuals at least 90 years of age from the Central Federal District of Russia
Mortality among long-living adults
Mortality among long-living adults within at least 1 year after inclusion in the study and factors associated with mortality will be assessed.
Time frame: at least 1 year after inclusion in the study
Morbidity among long-living adults
Morbidity among long-living adults within at least 1 year after inclusion in the study and factors associated with morbidity will be assessed.
Time frame: at least 1 year after inclusion in the study
Aging phenotypes
Identification of successful and unsuccessful aging phenotypes
Time frame: at least 2 years after inclusion in the study
Social, economic, and medical- history-related determinants
Identification of social, economic, and medical- history-related determinants of successful and unsuccessful aging, geriatric syndromes
Time frame: at least 2 years after inclusion in the study
Genetic determinants
Identification of the genetic determinants of successful and unsuccessful aging, geriatric syndromes
Time frame: at least 2 years after inclusion in the study
Epigenetic determinants
Identification of the epigenetic determinants (methylation sites) of successful and unsuccessful aging, geriatric syndromes
Time frame: at least 2 years after inclusion in the study
Metagenomic determinants
Identification of the metagenomic determinants (16S-rSeq) of successful and unsuccessful aging, geriatric syndromes
Time frame: at least 2 years after inclusion in the study
Started Dec 2019 (actual). Primary completion is estimated for Dec 2024, 60 months after the start.
Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 60 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Strategic Planning, of the Federal Medical and Biological Agency